| Iteos Therapeutics Inc (ITOS) | |||
|---|---|---|---|
| 14.24 -0.87 (-5.76%) | 06-09 16:00 | ||
| Open: | 15.19 | Pre. Close: | 15.11 |
| High: | 15.2 | Low: | 14.15 |
| Volume: | 201,625 | Market Cap: | 509(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 19.32  One year: 21.30 |
| Support: | Support1: 13.80 Support2: 11.48 |
| Resistance: | Resistance1: 16.54 Resistance2: 18.24 |
| Pivot: | 15.47  |
| Moving Averages: | MA(5): 15.08 MA(20): 15.30 MA(100): 16.17 MA(250): 19.05 |
| MACD: | MACD(12,26): 0.18 Signal(12,26,9): 0.33 |
| %K %D: | %K(14,3): 24.94 %D(3): 30.43 |
| RSI: | RSI(14): 44.42 |
| 52-Week: | High: 28.05 Low: 12.52 Change(%): -19.8 |
| Average Vol(K): | 3-Month: 266 10-Days: 373 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 15.229 - 15.316 | 15.316 - 15.41 |
| Low: | 13.919 - 14.01 | 14.01 - 14.109 |
| Close: | 14.068 - 14.227 | 14.227 - 14.399 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITOS ] has closed above bottom band by 17.4%. Bollinger Bands are 20.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 35.76 |
| Shares Float (M) | 24.52 |
| % Held by Insiders | 0.26 |
| % Held by Institutions | 105.22 |
| Shares Short (K) | 1780 |
| Shares Short Prior Month (K) | 1720 |
| Stock Financials | |
|---|---|
| EPS | 0.290 |
| Book Value (p.s.) | 18.240 |
| Profit Margin | 9.02 |
| Operating Margin | -14.22 |
| Return on Assets (ttm) | -1.4 |
| Return on Equity (ttm) | 1.8 |
| Qtrly Rev. Growth | -91.7 |
| Gross Profit (p.s.) | 7.484 |
| Sales Per Share | 3.571 |
| EBITDA (p.s.) | -0.484 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -113.75 |
| Levered Free Cash Flow (M) | -132.72 |
| Stock Valuation | |
|---|---|
| PE Ratio | 49.10 |
| PEG Ratio | |
| Price to Book value | 0.78 |
| Price to Sales | 3.99 |
| Price to Cash Flow | -4.48 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
